Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01IJJ
|
|||
| Former ID |
DIB003897
|
|||
| Drug Name |
MV-NIS
|
|||
| Synonyms |
MV-NIS (intratumoral, SCCHN); Measles virus encoding thyroidal sodium iodide symporter (intratumoral, Head and neck tumor), Nisco International Inc; MV-NIS (intratumoral, SCCHN), Nisco International Inc
Click to Show/Hide
|
|||
| Drug Type |
Oncolytic virus therapy
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42] | Phase 2 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [2] | ||
| Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 1 | [2] | ||
| Medulloblastoma [ICD-11: 2A00.10; ICD-10: C71.6; ICD-9: 191] | Phase 1 | [2], [3] | ||
| Urothelial carcinoma [ICD-11: 2C92.0] | Phase 1 | [4] | ||
| Company |
Nisco International Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02364713) MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT03171493) Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.